|Infectious keratitis: secreted bacterial proteins that mediate corneal damage.|
|Jump to Full Text|
|PMID: 23365719 Owner: NLM Status: PubMed-not-MEDLINE|
|Ocular bacterial infections are universally treated with antibiotics, which can eliminate the organism but cannot reverse the damage caused by bacterial products already present. The three very common causes of bacterial keratitis-Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae-all produce proteins that directly or indirectly cause damage to the cornea that can result in reduced vision despite antibiotic treatment. Most, but not all, of these proteins are secreted toxins and enzymes that mediate host cell death, degradation of stromal collagen, cleavage of host cell surface molecules, or induction of a damaging inflammatory response. Studies of these bacterial pathogens have determined the proteins of interest that could be targets for future therapeutic options for decreasing corneal damage.|
|Mary E Marquart; Richard J O'Callaghan|
Related Documents :
|894169 - Effects of protein synthesis inhibitors on angiotensin-stimulated and angiotensin-inhib...
24836509 - Identification and characterization of a novel fstk-like protein from spotted knifejaw ...
23551889 - What does s-palmitoylation do to membrane proteins?
23579319 - Relevance and application of sortase and sortase-dependent proteins in lactic acid bact...
24505349 - Rnase a does not translocate the alpha-hemolysin pore.
23023309 - Can protein carbonyl / glutathione ratio be used as a potential biomarker to assess oxi...
11135369 - A heat shock transcription factor like protein in the nuclear matrix compartment of the...
15872279 - Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute ...
8663389 - Plasma lipopolysaccharide-binding protein is found associated with a particle containin...
|Type: Journal Article Date: 2013-01-08|
|Title: Journal of ophthalmology Volume: 2013 ISSN: 2090-004X ISO Abbreviation: J Ophthalmol Publication Date: 2013|
|Created Date: 2013-01-31 Completed Date: 2013-02-01 Revised Date: 2013-04-18|
Medline Journal Info:
|Nlm Unique ID: 101524199 Medline TA: J Ophthalmol Country: United States|
|Languages: eng Pagination: 369094 Citation Subset: -|
|Department of Microbiology, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): J Ophthalmol
Journal ID (iso-abbrev): J Ophthalmol
Journal ID (publisher-id): JOP
Publisher: Hindawi Publishing Corporation
Copyright © 2013 M. E. Marquart and R. J. O'Callaghan.
Received Day: 31 Month: 5 Year: 2012
Accepted Day: 12 Month: 12 Year: 2012
Print publication date: Year: 2013
Electronic publication date: Day: 8 Month: 1 Year: 2013
Volume: 2013E-location ID: 369094
PubMed Id: 23365719
|Infectious Keratitis: Secreted Bacterial Proteins That Mediate Corneal Damage|
|Mary E. MarquartI1|
|Richard J. O'CallaghanI1*|
|Department of Microbiology, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216, USA
|Correspondence: *Richard J. O'Callaghan: firstname.lastname@example.org
[other] Academic Editor: Andrew G. Lee
The bacterial agents of infectious keratitis that have been studied in considerable detail are three of the most common causes of such infections, namely, Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa . The mechanisms underlying the tissue damage occurring during these infections have been studied in animal models. These infections are initiated by injection of bacteria into the corneal stroma, usually of New Zealand rabbits, or by the application of a topical drop of bacteria to a scarified cornea, usually of a mouse . Important to this research is the relative virulence of three forms of a bacterial strain, namely, the unaltered parent strain, its mutant deficient in a single specific gene coding for a secreted protein, and that same mutant strain following insertion of a functional copy of the mutated gene, a rescued strain. If the parent and rescue strains have statistically equivalent virulence and the mutant has significantly less virulence, then the mutated gene is recognized as a key virulence factor for the cornea . An additional method for establishing a specific gene as a virulence factor is to demonstrate that insertion of this specific gene into a nonpathogenic strain can significantly increase the virulence . These types of genetic analysis of virulence have defined multiple virulence factors for each of the three organisms commonly causing keratitis.
The importance of secreted proteins to keratitis can be illustrated by the study of certain nonpathogenic strains of bacteria. One observation that is not generally recognized, but is very important to consider, is that bacteria can be injected into a rabbit cornea and there grow from a small inoculum to millions of bacteria without causing any harm to the eye [4, 5]. For instance, Pseudomonas putida has been shown to grow well without mediating inflammation or corneal damage. This organism has LPS and other surface molecules, but it does not secrete proteins with corneal toxicity. This harmless infection is unlike that seen in an infection with the same P. putida strain after it has been modified by the insertion of a plasmid bearing a single P. aeruginosa gene coding for a secreted protease known to be a corneal virulence factor . In fact, the secretion of any one of the three known P. aeruginosa proteases can result in a virulent infection .
The value of knowing the mechanisms of bacterial corneal virulence relates to the need to limit such mechanisms before the tissue damage deprives the eye of vision. Application of an antibiotic to an infected eye can eliminate the infecting bacteria, but the damaging bacterial proteins already secreted can continue to mediate harmful inflammation and act directly to damage the cornea . The inclusion of a steroid during antibiotic therapy helps control the inflammatory process, but the actions of the secreted proteins are not affected by such therapy [7, 8]. Knowledge of the key mediators of tissue damage must be known to allow subsequent development of adjunct therapies to limit the action of these bacterial proteins. The prospect of using the immune system to inhibit these secreted bacterial proteins has a merit, but the bacterial enzymes found to be active in damaging corneal tissue may be poor immunogens or the antibody produced may not be effective in impeding the enzymatic activity . Thus, the mechanisms of keratitis have partially evaded the benefit of our current therapies. Also problematic is the emergence of bacteria with greater resistance to those antibiotics that were highly successful for many previous years; delays in obtaining an effective therapy provides time for the bacterial population to expand and to continue secreting the damaging proteins.
Pseudomonas corneal infections typically are associated with the use of contact lenses; that is, this is a man-made disease which was rarely a problem during the centuries prior to the contact lens use [10–12]. The organism, seen as a single gram-negative rod, is found in the environment, especially in moist places, so it is often available to contaminate the contact lens cases . Its adherence to plastic, coupled with its resistance to disinfectants, favors its introduction into the eye. These organisms can react with a corneal defect in the epithelium and they can pass through the epithelial barrier to the corneal stroma . Once these organisms reach the corneal stroma, the infections can rapidly progress toward melting of the cornea, an event attributed to the bacterial proteases, the activation of matrix metalloproteinases, and a damaging immune response that delivers among other things both reactive oxygen intermediates and host proteases .
P. aeruginosa is capable of secreting at least seven different proteases; these are elastase A (Las A), elastase B (Las B) , modified elastase , alkaline protease (AP), protease IV, pseudomonas aeruginosa small protease (PASP) , and the large exoprotease (Lep A) . Las A, Las B, modified elastase, and AP are metalloproteinases and may be produced by only some strains . These metalloproteases, especially Las B and AP, have been well studied in terms of their potential contribution to keratitis. These enzymes, especially Las B, upon injection into the corneal stroma can mediate considerable corneal damage [18, 19]. However, mutation of any one of these genes does not result in significantly reduced virulence of the organism [20–22]. Also, data exist showing that a strain with the potential to produce Las B fails to produce the enzyme during keratitis . P. putida, when supplied with a plasmid-borne gene for Las B, secretes Las B and demonstrates significant virulence in the infected rabbit cornea .
Lep A is a large protease that has been postulated to be a serine protease [16, 24]. The enzyme has been shown to be a virulence factor in a nonocular model of infection, but to date there are no published studies of its role in an ocular infection. An important study on Lep A showed that this enzyme can cleave a host transmembrane protein, designated the protease-activated receptor, which, when cleaved, can induce the production of cytokines . This study helps explain the inflammation that results when the bacteria producing proteases interact with corneal cells. This finding may also clarify the failure of P. putida to cause inflammatory changes as it grows in the cornea whereas the same stain engineered to produce a P. aeruginosa protease causes significant inflammation.
In contrast to the findings with the metalloproteases, the serine protease PIV is produced by essentially all strains able to cause keratitis [25, 26]. Mutation of the PIV gene has been shown to reduce the corneal virulence and the corneal virulence was restored following the insertion into the mutant strain of a plasmid coding for functional PIV . When a PIV-coding plasmid was inserted into P. putida, the organism acquired a significant amount of corneal virulence . PIV is able to cleave many proteins; in fact, few proteins with lysine escape cleavage by this protease [27, 28]. PIV will cleave poly-L-lysine to small peptides and free lysine. Cleaved by PIV are a variety of host defense proteins including immunoglobulins, complement components, antimicrobial peptides, and surfactants [27–29]. This protease contributes to virulence yet it is inefficient in cleaving collagens, the chief structural component of the corneal stroma. PIV has a molecular weight of 27,384 daltons and it can aggregate following exposure to SDS to enzymatically active masses of >200,000 daltons [27, 28]. Extensive immunizations with recombinant PIV were needed to produce even a relatively small amount of antibody to recombinant PIV or native PIV . The antibodies that were produced failed to inhibit the PIV catalytic activity or to provide protection from corneal damage due to the injection of active enzyme . The enzyme activity is susceptible to TLCK, a serine protease inhibitor, but unfortunately TLCK is highly toxic for eyes . The development of a nontoxic inhibitor could be very useful as an adjunct therapy for treating these infections.
The PASP protease has recently been analyzed relative to its role in keratitis and its properties as an enzyme [15, 30, 31]. The PASP gene is found in all strains tested and western blots of culture supernatants indicate that it is commonly expressed and secreted by both clinical isolates and established lab strains . A mutant lacking the PASP gene was engineered and found to have significantly less virulence than its parent or its rescued strain . The reduced virulence of the PASP-deficient mutant was demonstrated in both the rabbit intrastromal injection model and the mouse scratch model of keratitis. Injection of purified PASP into the rabbit cornea results in the destruction of the epithelium and the formation of erosions that can reach into the stroma . PASP, like PIV, is not neutralized by antibody to the recombinant PASP protein and the antibody does not protect the cornea from the injected enzyme or active infection .
The native PASP protein as found in culture supernatants has a molecular weight of 18,500 daltons [15, 30]. Studies of the purified enzyme or its recombinant protein showed that, unlike PIV, PASP does not efficiently cleave many host proteins [15, 30]. However, PASP is able to cleave collagens and this trait further distinguishes PASP from PIV. Cleavage of collagen by PASP suggests that this enzyme could be important in the destruction of the cornea . PASP will cleave peptides with lysine or arginine and it can convert poly-L-arginine or poly-L-lysine to small peptides and free amino acids. PASP appears to be a serine protease that is susceptible to serine protease inhibitors (e.g., TLCK) and partially inhibited, in a non-dose-dependent fashion, by high concentrations of EDTA (>100 mM). Enzymatic activity may require the formation of a homodimer in order to create the triad of three amino acids that form the active catalytic site .
The possibility exists that PIV provides the bacteria with a defense against multiple host defense molecules whereas PASP is active in cleaving the collagen-based structure of the cornea. Once a sizeable population of P. aeruginosa is established in a tissue site, a great deal of host response and tissue damage occurs before the infection is cleared.
Recent attention has been given to S. pneumoniae (pneumococcus) as a major cause of conjunctivitis outbreaks; however, this organism is also a common cause of infectious keratitis. Some epidemiologic studies identify the pneumococcus as the top cause of bacterial keratitis [32–39]. Most other reports show this bacterium and other Streptococcus species to be the causative agents most commonly encountered after P. aeruginosa and/or S. aureus [40–49]. Pneumococcal keratitis is not typically contact lens associated like P. aeruginosa, but predisposing conditions such as ocular trauma or surgery are factors in this disease [32, 33, 36, 39, 41, 48, 50–54].
The outer capsule of S. pneumoniae, while not protein but rather polysaccharide in composition, is likely the single most studied virulence factor of this bacterium. Pneumococcus normally resides in the human nasopharynx, and studies that date back to early bacterial virulence and transformation experiments such as those of Griffith  and Avery et al.  determined that the polysaccharide capsule (i.e., the characteristic that provides a “smooth” colony appearance) is the component necessary for S. pneumoniae to establish virulence and survive the host immune system. The central dogma of pneumococcal virulence in infections such as pneumonia, otitis media, meningitis, and septicemia is that noncapsular bacteria are avirulent. This long held rule was proven to be untrue for keratitis, as noncapsular strains were shown to cause as severe keratitis as their capsular counterparts in intrastromal infection models [57, 58].
Other than the capsule, the pneumococcus possesses a variety of proteins that have been characterized as virulence factors in nonocular models of disease. One such protein is pneumolysin, which is a toxin belonging to the family of bacterial cholesterol-dependent cytolysins. Pneumolysin is a 53 kDa protein that does not possess any known secretion signal sequence. This cytolysin was long thought to be an intracellular protein released from the bacteria upon cell lysis [59–61] and more recently reported to be cell wall associated . The mode of action of pneumolysin is the binding of monomers to cholesterol in host cell membranes, oligomerization at the membrane into 30–50 mers, and pore formation resulting in host cell lysis [63–65]. Lower concentrations of pneumolysin have been reported to stimulate leukocyte migration  and activate complement , thus stimulating the host inflammatory response and causing immunomediated damage to host tissues. Johnson and Allen first identified pneumolysin as responsible for ocular tissue damage during pneumococcal keratitis and characterized the biochemical features in vitro and the role in corneal virulence in vivo [68, 69]. Pneumolysin was verified to play a major role in keratitis as evidenced by reduced corneal virulence of a pneumolysin-deficient strain of S. pneumoniae compared to its parent strain in a rabbit intrastromal infection model . Mutation of the complement activation domain of pneumolysin also resulted in decreased corneal virulence, particularly inflammation . Added to these findings was that induction of leukopenia in rabbits resulted in significantly decreased severity of corneal damage following challenge with purified pneumolysin, indicating that pneumolysin was at least partly responsible for triggering the inflammatory response and causing immunomediated damage . Moreover, these and more recent studies have shown that pneumococcal keratitis continues to worsen in animal models when the bacteria have either reached a very low number or have been completely cleared [58, 71, 73, 74], underscoring the fact that corneal damage occurs despite eradication of the bacteria by antibiotics.
Efforts to find feasible pneumolysin inhibitors for the cornea have led to the use of soluble cholesterol as a topical therapy. Cholesterol was long known to be effective in inhibiting the hemolytic activity of pneumolysin in vitro , so this concept was employed in vivo. Topical cholesterol was shown to significantly reduce corneal inflammation in pneumococcal keratitis, purportedly by acting as a competitor for host cholesterol and neutralizing pneumolysin [76, 77]. Another attempt at targeting pneumolysin was the use of active and passive immunization in an animal model of keratitis [73, 78].
Proteins other than pneumolysin have been shown to be important for virulence in nonocular pneumococcal diseases but have not been associated with keratitis to date. Most of these proteins are located on the bacterial cell surface. A detailed review of pneumococcal virulence proteins is described elsewhere . Choline-binding proteins such as pneumococcal surface proteins A and C (PspA and PspC) are anchored by their bonds to choline in the cell wall. Other proteins are those containing LPXTG motifs that are recognized by bacterial sortase enzymes and are placed on the cell surface. One pneumococcal LPXTG protein of interest is neuraminidase A (NanA), which cleaves N-acetylneuraminic acid from host cell components and is suggested to be important for the binding of pneumococci to conjunctival epithelial cells by degrading host cell mucin . A variety of surface-associated proteins that do not fall into the categories of choline-binding proteins or LPXTG proteins have also been identified as involved in adherence, immune evasion, immune activation, and enzymatic reactions in nonocular models. Finally, at least four zinc metalloproteinases, including an IgA protease, have been identified with conflicting reports of their cellular locations. One of these proteases, ZmpC, has recently been shown to induce ectodomain shedding of a membrane-associated mucin from cultured conjunctival and corneal epithelial cells . Much remains unknown, however, as to the factors other than pneumolysin that contribute to pneumococcal keratitis.
S. aureus is the most common cause of bacterial keratitis and an important cause of other ocular infections [82–87]. This gram-positive coccus is found in human carriers who retain the organism in their anterior nares, throat, and perianal body sites . Specific strains of bacteria found in the flora around the eye provide the source of organisms that infect the eye . Humans are one reservoir for this organism, and multiple animals, especially pigs, have had an important role in the epidemiology of S. aureus . Keratitis occurs in individuals whose eyes are compromised by any of multiple changes including ocular surgery, contact lens use, trauma, viral infection, or other illnesses [91–93]. S. aureus is well known for its ability to evolve mechanisms of antibiotic resistance, making these infections among the most difficult to treat, and antibiotic resistance has increased since 2000 [94–97]. Although the antibiotic resistance of S. aureus is well known, what is less well recognized is that the gene transfer mechanisms that created the highly resistant strains can also transfer virulence traits [98–100]. Bacteriophage provides horizontal transfer of individual genes as well as clusters of virulence traits in a genetic unit designated as a pathogenicity island . Individual strains can develop a set of genes that allow their emergence as a cause of life-threatening infections.
The mechanisms involved in the initiation of keratitis are not yet understood. S. aureus has been shown to bind to human corneal cells in culture, a reaction mediated by the fibronectin-binding protein on the bacterial surface . Binding to the cornea can also be mediated by a collagen-binding adhesin on the S. aureus surface . Despite this binding ability and the availability of organisms from the flora surrounding the eye, keratitis infrequently develops. Possibly the greatest barrier protecting the eye is the bactericidal enzyme phospholipase A2, a component of the tear film [103, 104]. Once inflammation occurs in the anterior portion of the eye, the amount of phospholipase A2 increases, thus enhancing protection against bacteria . The topical application of S. aureus to a scarified rabbit cornea typically fails to cause an infection and results in the rapid loss of the bacteria . An active infection of the rabbit cornea has been achieved by treating a bacterial inoculum on a contact lens with spermidine and applying spermidine to the eye both before and after applying the contaminated lens to the corneal surface . Spermidine is able to bind to the bacterial surface and prevent bacterial killing by phospholipase A2. There is, however, one unique strain of S. aureus that can infect the scarified cornea without any other treatments; this strain is susceptible to the bactericidal action of tears but has demonstrated an enhanced invasion of human corneal epithelial cells in vitro [unpublished finding]. These data suggest that keratitis is dependent on bacterial binding and rapid penetration of the corneal epithelium.
The events occurring once bacteria reach the corneal stroma have been studied in some detail. The virulence of a prototype S. aureus strain (8325-4) following its injection into the rabbit cornea was significantly reduced by a mutation of the gene coding for alpha-toxin, a lytic cytotoxin produced by nearly all S. aureus strains . The alpha-toxin rescue strain had corneal virulence equivalent to that of the parent strain. Nanogram quantities of purified alpha-toxin were shown to cause extensive sloughing of the corneal epithelium, corneal edema, and severe iritis . The importance of this toxin was found also in the infection of the mouse cornea [108, 109]. Alpha-toxin is now recognized as the critical virulence factor in S. aureus pneumonia in humans . Research on the alpha-toxin's mechanism of action indicates that the toxin enters the cytoplasmic membrane and moves laterally until seven subunits unite into a circular arrangement forming a pore in the cytoplasmic membrane . The individual toxin molecules are thought to interact with caveolin-1 in the membrane to form a pore [111–113]. Inhibitors of the alpha-toxin-mediated lysis of erythrocytes have been developed by inserting lipid molecules into a cyclodextrin ring [114, 115]. One such inhibitor containing cholesterol has been shown to reduce the virulence of infections of the rabbit cornea . As was described above, the cyclodextrin-based inhibitor active against alpha-toxin is also active against pneumolysin .
Alpha-toxin is not the only virulence factor contributing to the tissue damage during S. aureus keratitis; important also is gamma-toxin, a two-component toxin produced by nearly all S. aureus strains [116, 117]. Deletion of the gamma-toxin genes from a prototype strain, strain Newman, resulted in a significant loss in corneal virulence and restoration of these genes enhanced the virulence back to that produced by the parent strain . A mutation in gamma-toxin or inhibition of this toxin has also been shown to reduce the virulence of endophthalmitis caused by S. aureus [119, 120]. Gamma-toxin is composed of an F component and an S component that are each nontoxic when tested alone [121, 122]. The S component is thought to bind to the target cell and only then will the F component bind . The combination of F and S can move laterally in the cell membrane and multiple F-S pairs can combine into a ring that penetrates the membrane causing cell lysis [122–124]. A cyclodextrin-based inhibitor for the gamma-toxin has very recently been identified as an inhibitor of the gamma-toxin-mediated lysis of erythrocytes, but it has not been tested yet in infected corneas .
Gamma-toxin is only one of several two-component toxins produced by S. aureus and each has its own F and S components . Gamma-toxin is composed of two proteins, either HlgA and HlgB or HlgC and HlgB; likewise the Panton-Valentine leucocidin (PVL), a well-recognized toxin, is composed of its two proteins, LukF-PV and LukS-PV . Lesser known proteins involved in toxic activity include three S-type proteins LukM, LukS-R, and Luk E and two F-type proteins LukF-R and Luk D [122–124]. There is about 60–70% sequence homology among the various F components and a fairly similar degree of homology among the multiple S components . The two-component toxin systems of S. aureus are complicated by the fact that the F component of one toxin can bind to the S component of another toxin . Therefore, multiple unique toxins can be formed by one component from each of two different toxins (e.g., the F of one toxin with the S of another toxin). Each combination of an F and an S component can have its own specific toxicity . How these toxins relate to corneal damage is yet to be resolved, but because these toxins are homologous with gamma-toxin, it is likely that at least one such toxin has corneal toxicity.
Another molecule with proven ability to serve as a corneal virulence factor is the setnm-1 gene . This gene is a part of a cluster of genes for super-antigen-like proteins involved in virulence for infections in nonocular sites . These genes are found in a pathogenicity island on the chromosome of many S. aureus isolates and they are thought to have been derived from a phage genome . The genes in this island, other than setnm-1, are known to inhibit host immune mediators such as complement or IgA. Only setnm-1 has been shown to mediate corneal damage; that is, a mutant deficient in this gene has significantly reduced corneal virulence as compared to its parent and rescued strains . It is not yet clear how setnm-1 functions as a virulence factor, but one possibility is that it has protease activity . Injection of the protein produced by the setnm-1 gene can cause extensive corneal damage, an event not expected for a super-antigen-like protein.
The fundamental treatment of bacterial keratitis is based on the action of bactericidal antibiotic therapy to eliminate the bacteria that secrete the toxic proteins. A key issue in treatment is that the cornea has rapidly replicating bacteria prior to the onset of severe symptoms, and later, when symptoms are present, bacteria with a much reduced rate of bacterial replication predominate. Key drugs, such as fluoroquinolones, are far more effective on replicating than nonreplicating bacteria, so the treatment of the cornea needs to be prompt, aggressive, and prolonged. Global regulation of gene expression in bacteria limits the production of important toxins and enzymes until the bacteria are no longer rapidly replicating . Once replication slows or stops, the toxins are secreted; thus, nonreplicating bacteria are hard to kill and they are efficient toxin producers. The points to be stressed are that prompt bactericidal therapy is a must and that the toxins once produced cannot now be eliminated without a loss of healthy tissue.
|1.||Asbell P,Stenson S. Ulcerative keratitis. Survey of 30 years’ laboratory experienceArchives of OphthalmologyYear: 1982100177802-s2.0-00200781926173033|
|2.||Girgis DO,Sloop GD,Reed JM,O’Callaghan RJ. A new topical model of Staphylococcus corneal infection in the mouseInvestigative Ophthalmology and Visual ScienceYear: 2003444159115972-s2.0-003737798712657597|
|3.||Salyers AA,Whitt DD. Bacterial Pathogenesis, a Molecular ApproachYear: 20022nd editionWashington, DC, USAASM Press|
|4.||Traidej M,Caballero AR,Marquart ME,Thibodeaux BA,O’Callaghan RJ. Molecular analysis of Pseudomonas aeruginosa protease IV expressed in Pseudomonas putidaInvestigative Ophthalmology and Visual ScienceYear: 20034411901962-s2.0-003725130912506074|
|5.||Thibodeaux BA,Caballero AR,Marquart ME,Tommassen J,O’Callaghan RJ. Corneal virulence of Pseudomonas aeruginosa elastase B and alkaline protease produced by Pseudomonas putidaCurrent Eye ResearchYear: 20073243733862-s2.0-3424738203517453960|
|6.||O’Callaghan RJ. Role of exoproteins in bacterial keratitis: the Fourth Annual Thygeson Lecture, presented at the Ocular Microbiology and Immunology Group Meeting, November 7, 1998CorneaYear: 19991855325372-s2.0-003283578010487425|
|7.||Hobden JA,Hill JM,Engel LS,O’Callaghan RJ. Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofenAntimicrobial Agents and ChemotherapyYear: 1993379185618592-s2.0-00272549728239596|
|8.||Hobden JA,Engel LS,Hill JM,Callegan MC,O’Callaghan RJ. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitisCurrent Eye ResearchYear: 19931254694732-s2.0-00273017248344070|
|9.||Thibodeaux BA,Caballero AR,Dajcs JJ,Marquart ME,Engel LS,O’Callaghan RJ. Pseudomonas aeruginosa protease IV: a corneal virulence factor of low immunogenicityOcular Immunology and InflammationYear: 2005132-31691822-s2.0-2514451363816019676|
|10.||Ogushi Y,Eguchi H,Kuwahara T,Hayabuchi N,Kawabata M. Molecular genetic investigations of contaminated contact lens storage cases as reservoirs of Pseudomonas aeruginosa keratitisJapanese Journal of OphthalmologyYear: 20105465505542-s2.0-7875163949821191715|
|11.||Poggio EC,Glynn RJ,Schein OD,et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lensesNew England Journal of MedicineYear: 1989321127797832-s2.0-00244411052770809|
|12.||Schein OD,Poggio EC. Ulcerative keratitis in contact lens wearers. Incidence and risk factorsCorneaYear: 19909supplement 1S55S582-s2.0-00252883182347199|
|13.||Ramirez JC,Fleiszig SM,Sullivan AB,Tam C,Borazani R,Evans DJ. Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aeruginosa requires the phospholipase domain of exoUInvestigative Ophthalmology and Visual ScienceYear: 201253144845322167094|
|14.||Twining SS,Kirschner SE,Mahnke LA,Frank DW. Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteinsInvestigative Ophthalmology and Visual ScienceYear: 1993349269927122-s2.0-00271796228344792|
|15.||Marquart ME,Caballero AR,Chomnawang M,Thibodeaux BA,Twining SS,O’Callaghan RJ. Identification of a novel secreted protease from Pseudomonas aeruginosa that causes corneal erosionsInvestigative Ophthalmology and Visual ScienceYear: 20054610376137682-s2.0-3294448169016186360|
|16.||Kida Y,Higashimoto Y,Inoue H,Shimizu T,Kuwano K. A novel secreted protease from Pseudomonas aeruginosa activates NF-κB through protease-activated receptorsCellular MicrobiologyYear: 2008107149115042-s2.0-4524908302718331590|
|17.||Nicas TI,Iglewski BH. Production of elastase and other exoproducts by environmental isolates of Pseudomonas aeruginosaJournal of Clinical MicrobiologyYear: 19862359679692-s2.0-00225741873086372|
|18.||Matsumoto K,Shams NBK,Hanninen LA,Kenyon KR. Cleavage and activation of corneal matrix metalloproteases by Pseudomonas aeruginosa proteasesInvestigative Ophthalmology and Visual ScienceYear: 1993346194519532-s2.0-00272074928491548|
|19.||Kessler E,Kennah HE,Brown SI. Pseudomonas protease. Purification, partial characterization, and its effect on collagen, proteoglycan, and rabbit corneasInvestigative Ophthalmology and Visual ScienceYear: 19771664884972-s2.0-0017683484405343|
|20.||White CD,Alionte LG,Cannon BM,Caballero AR,O’Callaghan RJ,Hobden JA. Corneal virulence of LasA protease—deficient Pseudomonas aeruginosa PAO1CorneaYear: 20012066436462-s2.0-003489485511473168|
|21.||Pillar CM,Hazlett LD,Hobden JA. Alkaline protease-deficient mutants of Pseudomonas aeruginosa are virulent in the eyeCurrent Eye ResearchYear: 20002137307392-s2.0-003453202111120561|
|22.||Hobden JA. Pseudomonas aeruginosa proteases and corneal virulenceDNA and Cell BiologyYear: 2002215-63913962-s2.0-003637784812167241|
|23.||Kernacki KA,Hobden JA,Hazlett LD,Fridman R,Berk RS. In vivo bacterial protease production during Pseudomonas aeruginosa corneal infectionInvestigative Ophthalmology and Visual ScienceYear: 1995367137113782-s2.0-00290654127775115|
|24.||Kida Y,Shimizu T,Kuwano K. Cooperation between LepA and PlcH contributes to the in vivo virulence and growth of Pseudomonas aeruginosa in miceInfection and ImmunityYear: 20117912112192-s2.0-7865086072621041488|
|25.||Caballero A,Thibodeaux B,Marquart M,Traidej M,O’Callaghan RJ. Pseudomonas keratitis: protease IV gene conservation, distribution, and production relative to virulence and other pseudomonas proteasesInvestigative Ophthalmology and Visual ScienceYear: 20044525225302-s2.0-094228724214744894|
|26.||Conibear T,Wilcox M,Flanagan JR,Zhu H. Characterization of protease IV expression in Pseudomonas aeruginosa clinical isolatesJournal of Medical MicrobiologyYear: 201261, part 218019021921113|
|27.||Engel LS,Hill JM,Caballero AR,Green LC,O’Callaghan RJ. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosaJournal of Biological ChemistryYear: 19982732716792167972-s2.0-00324791549642237|
|28.||Caballero AR,Moreau JM,Engel LS,Marquart ME,Hill JM,O’Callaghan RJ. Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteasesAnalytical BiochemistryYear: 200129023303372-s2.0-003586955511237336|
|29.||Malloy JL,Veldhuizen RAW,Thibodeaux BA,O’Callaghan RJ,Wright JR. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functionsAmerican Journal of Physiology/Lung Cell Molecular PhysiologyYear: 20052882L409L4182-s2.0-12144257634|
|30.||Tang A,Marquart ME,Fratkin JD,et al. Properties of PASP: a pseudomonas protease capable of mediating corneal erosionsInvestigative Ophthalmology and Visual ScienceYear: 2009508379438012-s2.0-6834910499219255155|
|31.||O'Callaghan RJ,Tang A,Marquart ME,Caballero AR. Pseudomonas aeruginosa Small Protease (PASP), a keratitis virulence factorInvestigative Ophthalmology and Visual ScienceYear: 201253 E-abstract 6128.|
|32.||Al Otaibi AG,Allam K,Damri AJ,Shamri AA,Kalantan H,Mousa A. Childhood microbial keratitisOman Journal of OphthalmologyYear: 201251283122557873|
|33.||Bashir G,Shah A,Thokar MA,Rashid S,Shakeel S. Bacterial and fungal profile of corneal ulcers—a prospective studyIndian Journal of Pathology and MicrobiologyYear: 20054822732772-s2.0-33746039751|
|34.||Bharathi MJ,Ramakrishnan R,Vasu S,Meenakshi R,Palaniappan R. Aetiological diagnosis of microbial keratitis in South India—a study of 1618 casesIndian Journal of Medical MicrobiologyYear: 2002201192417657018|
|35.||Bharathi MJ,Ramakrishnan R,Vasu S,Meenakshi R,Shivkumar C,Palaniappan R. Epidemiology of bacterial keratitis in a referral centre in south IndiaIndian Journal of Medical MicrobiologyYear: 20032142392452-s2.0-034439342917643035|
|36.||Bharathi MJ,Ramakrishnan R,Meenakshi R,Padmavathy S,Shivakumar C,Srinivasan M. Microbial keratitis in South India: influence of risk factors, climate, and geographical variationOphthalmic EpidemiologyYear: 200714261692-s2.0-3424761600617464852|
|37.||Feilmeier MR,Sivaraman KR,Oliva M,Tabin GC,Gurung R. Etiologic diagnosis of corneal ulceration at a Tertiary Eye Center in Kathmandu, NepalCorneaYear: 20102912138013852-s2.0-7865051204420847686|
|38.||Furlanetto RL,Andreo EGV,Finotti IGA,Arcieri ES,Ferreira MA,Rocha FJ. Epidemiology and etiologic diagnosis of infectious keratitis in Uberlandia, BrazilEuropean Journal of OphthalmologyYear: 20102034985032-s2.0-7795288436520175055|
|39.||Katiyar R,Deorukhkar S,Saini S. Epidemiological features and laboratory results of bacterial and fungal keratitis: a five-year study at a rural tertiary-care hospital in western Maharashtra, IndiaSingapore Medical JournalYear: 201253426426722511050|
|40.||Bharathi MJ,Ramakrishnan R,Shivakumar C,Meenakshi R,Lionalraj D. Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south IndiaIndian Journal of OphthalmologyYear: 20105864975072-s2.0-7814943316720952834|
|41.||Boonpasart S,Kasetsuwan N,Puangsricharern V,Pariyakanok L,Jittpoonkusol T. Infectious keratitis at King Chulalongkorn Memorial Hospital: a-12-year retrospective study of 391 casesJournal of the Medical Association of ThailandYear: 200285supplement 1S217S2302-s2.0-003662188512188415|
|42.||Lalitha P,Srinivasan M,Manikandan P,et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitisClinical Infectious DiseasesYear: 201254101381138722447793|
|43.||Norina TJ,Raihan S,Bakiah S,Ezanee M,Liza-Sharmini AT,Wan Hazzabah WH. Microbial keratitis: aetiological diagnosis and clinical features in patients admitted to Hospital Universiti Sains MalaysiaSingapore Medical JournalYear: 200849167712-s2.0-3904913830318204773|
|44.||Ramesh S,Ramakrishnan R,Bharathi MJ,Amuthan M,Viswanathan S. Prevalence of bacterial pathogens causing ocular infections in South IndiaIndian Journal of Pathology and MicrobiologyYear: 20105322812862-s2.0-77953932328|
|45.||Schaefer F,Bruttin O,Zografos L,Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological studyBritish Journal of OphthalmologyYear: 20018578428472-s2.0-003492520411423460|
|46.||Shalchi Z,Gurbaxani A,Baker M,Nash J. Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United KingdomOphthalmologyYear: 2011118112161216521764458|
|47.||Varaprasathan G,Miller K,Lietman T,et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor FoundationCorneaYear: 20042343603642-s2.0-214271742215097130|
|48.||Wagoner MD,Al-Swailem SA,Sutphin JE,Zimmerman MB. Bacterial keratitis after penetrating keratoplasty. Incidence, microbiological profile, graft survival, and visual outcomeOphthalmologyYear: 20071146107310792-s2.0-3424853206217275089|
|49.||Yilmaz S,Ozturk I,Maden A. Microbial keratitis in West Anatolia, Turkey: a retrospective reviewInternational OphthalmologyYear: 20072742612682-s2.0-3444710349817453152|
|50.||Cosar CB,Cohen EJ,Rapuano CJ,Laibson PR. Clear corneal wound infection after phacoemulsificationArchives of OphthalmologyYear: 200111912175517592-s2.0-003520828311735784|
|51.||Lifshitz T,Levy J,Raiskup F,Klemperer I,Frucht-Pery J. Two cases of pneumococcal keratitis following myopic LASIKJournal of Refractive SurgeryYear: 20052154985012-s2.0-2514450598516209450|
|52.||Mulet ME,Pérez-Santonja JJ,Ferrer C,Alió JL. Microbial keratitis after intrastromal corneal ring segment implantationJournal of Refractive SurgeryYear: 20102653643692-s2.0-7795305281520506994|
|53.||Nubile M,Carpineto P,Lanzini M,Ciancaglini M,Zuppardi E,Mastropasqua L. Multilayer amniotic membrane transplantation for bacterial keratitis with corneal perforation after hyperopic photorefractive keratectomy. Case report and literature reviewJournal of Cataract and Refractive SurgeryYear: 2007339163616402-s2.0-3454802234417720083|
|54.||Rehany U,Balut G,Lefler E,Rumelt S. The prevalence and risk factors for donor corneal button contamination and its association with ocular infection after transplantationCorneaYear: 20042376496542-s2.0-474434908315448488|
|55.||Griffith F. The significance of pneumococcal typesJournal of HygieneYear: 192827211315920474956|
|56.||Avery OT,MacLeod CM,McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type IIIJournal of Experimental MedicineYear: 194479113715819871359|
|57.||Norcross EW,Tullos NA,Taylor SD,Sanders ME,Marquart ME. Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infectionCurrent Eye ResearchYear: 20103597877982-s2.0-7795616721720795860|
|58.||Reed JM,O’Callaghan RJ,Girgis DO,McCormick CC,Caballero AR,Marquart ME. Ocular virulence of capsule-deficient Streptococcus pneumoniae in a rabbit keratitis modelInvestigative Ophthalmology and Visual ScienceYear: 20054626046082-s2.0-1394428168615671288|
|59.||Johnson MK. Cellular location of pneumolysinFEMS Microbiology LettersYear: 1977252432452-s2.0-0017661629|
|60.||Kanclerski K,Möllby R. Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin)Journal of Clinical MicrobiologyYear: 19872522222252-s2.0-00230685743818918|
|61.||Steinfort C,Wilson R,Mitchell T,et al. Effect of Streptococcus pneumoniae on human respiratory epithelium in vitroInfection and ImmunityYear: 1989577200620132-s2.0-00243276772731981|
|62.||Price KE,Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniaeJournal of BacteriologyYear: 20091917216321682-s2.0-6404909285219168620|
|63.||Morgan PJ,Hyman SC,Byron O,Andrew PW,Mitchell TJ,Rowe AJ. Modeling the bacterial protein toxin, pneumolysin, in its monomeric and oligomeric formJournal of Biological ChemistryYear: 19942694125315253202-s2.0-00280628767929224|
|64.||Morgan PJ,Hyman SC,Rowe AJ,Mitchell TJ,Andrew PW,Saibil HR. Subunit organisation and symmetry of pore-forming, oligomeric pneumolysinFEBS LettersYear: 1995371177802-s2.0-00291539447664888|
|65.||Tilley SJ,Orlova EV,Gilbert RJC,Andrew PW,Saibil HR. Structural basis of pore formation by the bacterial toxin pneumolysinCellYear: 200512122472562-s2.0-1744440561015851031|
|66.||Johnson MK,Boese-Marrazzo D,Pierce WA Jr.. Effects of pneumolysin on human polymorphonuclear leukocytes and plateletsInfection and ImmunityYear: 19813411711762-s2.0-00193895687298179|
|67.||Paton JC,Rowan Kelly B,Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysinInfection and ImmunityYear: 1984433108510872-s2.0-00213632046698602|
|68.||Johnson MK,Allen JH. Ocular toxin of the pneumococcusAmerican Journal of OphthalmologyYear: 19717211751802-s2.0-00152457134398340|
|69.||Johnson MK,Allen JH. The role of cytolysin in pneumococcal ocular infectionAmerican Journal of OphthalmologyYear: 1975803, part 25185212-s2.0-0006227142240276|
|70.||Johnson MK,Hobden JA,Hagenah M,O’Callaghan RJ,Hill JM,Chen S. The role of pneumolysin in ocular infections with Streptococcus pneumoniaeCurrent Eye ResearchYear: 1990911110711142-s2.0-00255980362095322|
|71.||Johnson MK,Callegan MC,Engel LS,et al. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit corneaCurrent Eye ResearchYear: 19951442812842-s2.0-00288986727606914|
|72.||Harrison JC,Karcioglu ZA,Johnson MK. Response of leukopenic rabbits to pneumococcal toxinCurrent Eye ResearchYear: 1982-19832107057102-s2.0-00204398687186437|
|73.||Green SN,Sanders M,Moore QC III,et al. Protection from Streptococcus pneumoniae keratitis by passive immunization with pneumolysin antiserumInvestigative Ophthalmology and Visual ScienceYear: 20084912902942-s2.0-3954908619018172105|
|74.||Moore QC III,McCormick CC,Norcross EW,et al. Development of a Streptococcus pneumoniae keratitis model in miceOphthalmic ResearchYear: 20094231411462-s2.0-6765100520419628954|
|75.||Johnson MK,Geoffroy C,Alouf JE. Binding of cholesterol by sulfhydryl-activated cytolysinsInfection and ImmunityYear: 1980271971012-s2.0-00189179077358434|
|76.||Marquart ME,Monds KS,McCormick CC,et al. Cholesterol as treatment for pneumococcal keratitis: cholesterol-specific inhibition of pneumolysin in the corneaInvestigative Ophthalmology and Visual ScienceYear: 2007486266126662-s2.0-3434722440517525197|
|77.||Sanders ME,Tullos NA,Taylor SD,et al. Moxifloxacin and cholesterol combined treatment of pneumococcal keratitisCurrent Eye ResearchYear: 20103512114211472-s2.0-7864974562521121810|
|78.||Norcross EW,Sanders ME,Moore QC III,et al. Active immunization with pneumolysin versus 23-valent polysaccharide vaccine for Streptococcus pneumoniae keratitisInvestigative Ophthalmology and Visual ScienceYear: 201152129232924322039231|
|79.||Mitchell AM,Mitchell TJ. Streptococcus pneumoniae: virulence factors and variationClinical Microbiology and InfectionYear: 20101654114182-s2.0-7795290333420132250|
|80.||Williamson YM,Gowrisankar R,Longo DL,et al. Adherence of nontypeable Streptococcus pneumoniae to human conjunctival epithelial cellsMicrobial PathogenesisYear: 20084431751852-s2.0-3854914193017936571|
|81.||Govindarajan B,Menon BB,Spurr-Michaud S,et al. A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrierPLoS OneYear: 201273, article e32418|
|82.||Liesegang TJ. Kaufman HE,Baron BA,McDonald MABacterial keratitisThe CorneaYear: 1998Boston, Mass, USAButterworth-Heineman|
|83.||Wong VW,Lai TY,Chi SC,Lam DS. Pediatric ocular surface infections: a 5-year review of demographics, clinical features, risk factors, microbiological results, and treatmentCorneaYear: 2011309995100221705879|
|84.||Jeng BH,Gritz DC,Kumar AB,et al. Epidemiology of ulcerative keratitis in Northern CaliforniaArchives of OphthalmologyYear: 20101288102210282-s2.0-7795545936720697003|
|85.||Kerr N,Stern GA. Bacterial keratitis associated with vernal keratoconjunctivitisCorneaYear: 19921143553592-s2.0-00267419771424658|
|86.||Palmer ML,Hyndiuk RA. Contact lens-related infectious keratitisInternational Ophthalmology ClinicsYear: 199333123492-s2.0-00274149098349426|
|87.||Sowka JW,Gurwood AS,Kabat AG. Handbook of Ocular Disease Management Web Site: Bacterial KeratitisYear: 2001Jobson Publishing|
|88.||Tacconelli E,Johnson AP. National guidelines for decolonization of methicillin-resistant Staphylococcus aureus carriers: the implications of recent experience in the NetherlandsThe Journal of Antimicrobial ChemotherapyYear: 201166102195219821807740|
|89.||Speaker MG,Milch FA,Shah MK,Eisner W,Kreiswirth BN. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitisOphthalmologyYear: 19919856396492-s2.0-00258753542062496|
|90.||Köck R,Harlizius J,Bressan N,et al. Prevalence and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) among pigs on German farms and import of livestock-related MRSA into hospitalsEuropean Journal of Clinical Microbiology and Infectious DiseasesYear: 20092811137513822-s2.0-70449529647|
|91.||Cheung J,Slomovic AR. Microbial etiology and predisposing factors among patients hospitalized for corneal ulcerationCanadian Journal of OphthalmologyYear: 19953052512552-s2.0-00291604198529159|
|92.||Ormerod LD,Hertzmark E,Gomez DS,Stabiner RG,Schanzlin DJ,Smith RE. Epidemiology of microbial keratitis in Southern California. A multivariate analysisOphthalmologyYear: 19879410132213332-s2.0-00232299893317183|
|93.||Coster DJ,Badenoch PR. Host, microbial, and pharmacological factors affecting the outcome of suppurative keratitisBritish Journal of OphthalmologyYear: 1987712961012-s2.0-00231485933103672|
|94.||Asbell PA,Sahm DF,Shaw M,Draghi DC,Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005Journal of Cataract and Refractive SurgeryYear: 20083458148182-s2.0-4294913328118471638|
|95.||Dave SB,Toma HS,Kim SJ. Ophthalmic antibiotic use and multidrug-resistant Staphylococcus epidermidis: a controlled, longitudinal studyOphthalmologyYear: 2011118102035204021856006|
|96.||Morrissey I,Burnett R,Viljoen L,Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002The Journal of InfectionYear: 20044921091142-s2.0-324279343515236917|
|97.||McDonald M,Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolonesJournal of Cataract and Refractive SurgeryYear: 2010369158815982-s2.0-7795558913520692574|
|98.||Schmidt H,Hensel M. Pathogenicity islands in bacterial pathogenesisClinical Microbiology ReviewsYear: 200417114562-s2.0-164247509514726454|
|99.||Enright MC. Lindsay JAThe population structure of Staphylococcus aureusStaphylococcus Molecular GeneticsYear: 2008Norfolk, UKCaister Academic Press2943|
|100.||McAdam PR,Templeton KE,Edwards GF,et al. Molecular tracing of the emergence, adaptation, and transmission of hospital-associated methicillin-resistant Staphylococcus aureusProceedings of the National Academy of Sciences of the United States of AmericaYear: 2012109239107911222586109|
|101.||Jett BD,Gilmore MS. Internalization of Staphylococcus aureus by human corneal epithelial cells: role of bacterial fibronectin-binding protein and host cell factorsInfection and ImmunityYear: 2002708469747002-s2.0-003607601412117986|
|102.||Rhem MN,Lech EM,Patti JM,et al. The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitisInfection and ImmunityYear: 2000686377637792-s2.0-003407529610816547|
|103.||Girgis DO,Dajcs JJ,O’Callaghan RJ. Phospholipase A2 activity in normal and Staphylococcus aureus-infected rabbit eyesInvestigative Ophthalmology and Visual ScienceYear: 20034411972022-s2.0-003720747712506075|
|104.||Moreau JM,Girgis DO,Hume EBH,Dajcs JJ,Austin MS,O’Callaghan RJ. Phospholipase A2 in rabbit tears: a host defense against Staphylococcus aureusInvestigative Ophthalmology and Visual ScienceYear: 20014210234723542-s2.0-003484872911527949|
|105.||Hume EBH,Dajcs JJ,Moreau JM,Sloop GD,Willcox MDP,O’Callaghan RJ. Staphylococcus corneal virulence in a new topical model of infectionInvestigative Ophthalmology and Visual ScienceYear: 20014212290429082-s2.0-003476617511687535|
|106.||O’Callaghan RJ,Callegan MC,Moreau JM,et al. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infectionInfection and ImmunityYear: 1997655157115782-s2.0-00309348219125532|
|107.||Moreau JM,Sloop GD,Engel LS,Hill JM,O’Callaghan RJ. Histopathological studies of staphylococcal alpha-toxin: effects on rabbit corneasCurrent Eye ResearchYear: 19971612122112282-s2.0-00306587749426955|
|108.||Girgis DO,Sloop GD,Reed JM,O’Callaghan RJ. A new topical model of Staphylococcus corneal infection in the mouseInvestigative Ophthalmology and Visual ScienceYear: 2003444159115972-s2.0-003737798712657597|
|109.||Girgis DO,Sloop GD,Reed JM,O’Callaghan RJ. Effects of toxin production in a murine model of Staphylococcus aureus keratitisInvestigative Ophthalmology and Visual ScienceYear: 2005466206420702-s2.0-2214443595115914624|
|110.||Kebaier C,Chamberland RC,Allen IC,et al. Staphylococcus aureusα-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasomeJournal of Infectious DiseasesYear: 2012205580781722279123|
|111.||Menestrina G,Serra MD,Prévost G. Mode of action of β-barrel pore-forming toxins of the staphylococcal α-hemolysin familyToxiconYear: 20013911166116722-s2.0-003486944411595629|
|112.||Pany S,Vijayvargia R,Krishnasastry MV. Caveolin-1 binding motif of α-hemolysin: its role in stability and pore formationBiochemical and Biophysical Research CommunicationsYear: 2004322129362-s2.0-414306360115313169|
|113.||Vijayvargia R,Suresh CG,Krishnasastry MV. Functional form of caveolin-1 is necessary for the assembly of α-hemolysinBiochemical and Biophysical Research CommunicationsYear: 20043243113011362-s2.0-544426252915485672|
|114.||McCormick CC,Caballero AR,Balzli CL,Tang A,O’Callaghan RJ. Chemical inhibition of alpha-toxin, a key corneal virulence factor of Staphylococcus aureusInvestigative Ophthalmology and Visual ScienceYear: 2009506284828542-s2.0-6684911120919136695|
|115.||Weeks AC,Balzli CL,Caballero AR,Tang A,O'Callaghan RJ. Identification and potency of cyclodextrin-lipid inhibitors of Staphylococcus aureusα-toxinCurrent Eye ResearchYear: 2012372879322050601|
|116.||Freer JH,Arbuthnott JP. Toxins of Staphylococcus aureusPharmacology and TherapeuticsYear: 1982191551062-s2.0-00202850816763705|
|117.||Clyne M,De Azavedo J,Carlson E,Arbuthnott J. Production of gamma-hemolysin and lack of production of alpha-hemolysin by Staphylococcus aureus strains associated with toxic shock syndromeJournal of Clinical MicrobiologyYear: 19882635355392-s2.0-00238840653356791|
|118.||Dajcs JJ,Austin MS,Sloop GD,et al. Corneal pathogenesis of Staphylococcus aureus strain NewmanInvestigative Ophthalmology and Visual ScienceYear: 2002434110911152-s2.0-003620287511923253|
|119.||Supersac G,Piémont Y,Kubina M,Prévost G,Foster TJ. Assessment of the role of gamma-toxin in experimental endophthalmitis using a hlg-deficient mutant of Staphylococcus aureusMicrobial PathogenesisYear: 19982442412512-s2.0-03454870139533895|
|120.||Arana AM,Balzli CL,Weeks AC,Tang A,Caballero AR,O'Callaghan RJ. Pathogenesis of Staphylococcus aureus endophthalmitis: analysis of alpha-toxin and gamma-toxin in the rabbit anterior chamberInvestigative Ophthalmology & Visual ScienceYear: 201253 E-abstract 2772.|
|121.||Yamashita K,Kawai Y,Tanaka Y,et al. Crystal structure of the octameric pore of staphylococcal γ-hemolysin reveals the β-barrel pore formation mechanism by two componentProceeding of the National Academy of Sciences of the United States of AmericaYear: 2011108421731417319|
|122.||Gravet A,Colin DA,Keller D,Girardot R,Monteil H,Prevost G. Characterization of a novel structural member, LukE-LukD, of the bi-component staphylococcal leucotoxins familyFEBS LettersYear: 199843622022089781679|
|123.||Szmigieski S,Prevost G,Monteil H,Colin DA,Jelaszewicz J. Leukocidal toxins of staphylococciZentralblatt für BakteriologieYear: 19992892185201|
|124.||Sugawara N,Tomita T,Kamio Y. Assembly of Staphylococcus aureusγ-hemolysin into a pore-forming ring- shaped complex on the surface of human erythrocytesFEBS LettersYear: 19974102-33333372-s2.0-00307405559237657|
|125.||Caballero AR,Foster TJ,Monk IR,Tang A,Balzli CL,O'Callaghan RJ. Ocular pathology of a Staphylococcus aureus mutant lacking a recently discovered virulence factorInvestigative Ophthalmology and Visual ScienceYear: 201051 E-abstract 3891.|
|126.||Fraser JD,Proft T. The bacterial superantigen and superantigen-like proteinsImmunological ReviewsYear: 200822512262432-s2.0-5204912329918837785|
|127.||Caballero AR,McCormick CC,Tang A,O'Callaghan RJ. Isolation and characterization of a new Staphylococcus aureus proteaseInvestigative Ophthalmology and Visual ScienceYear: 200849 abstract 5514.|
|128.||Balaban N,Novick RP. Autocrine regulation of toxin synthesis by Staphylococcus aureusProceedings of the National Academy of Sciences of the United States of AmericaYear: 1995925161916232-s2.0-00289441177533297|
Previous Document: Helminths: Immunoregulation and Inflammatory Diseases-Which Side Are Trichinella spp. and Toxocara s...
Next Document: Ischemia induces release of endogenous amino acids from the cerebral cortex and cerebellum of develo...